Rebranding Invizyne to eXoZymes Signifies a Sustainable Paradigm Shift in Chemical Production Leveraging AI-Engineered Enzymes

Rhea-AI Summary

Invizyne Technologies announced its corporate rebranding to eXoZymes Inc, with its stock trading symbol changing from IZTC to EXOZ on the Nasdaq Capital Market. The company introduces 'exozymes' as a new scientific concept, positioning it as the successor to synthetic biology (SynBio), particularly focusing on industrial-scale production.

eXoZymes specializes in AI-engineered enzymes designed to operate outside living cells in bioreactors, transforming feedstocks into valuable chemicals, medicines, and biofuels. The company emphasizes this technology's potential to replace traditional chemical production methods with sustainable alternatives. The development process, powered by AI and enzymes, significantly reduces production timelines, with the company expecting to announce a new chemical development completed in just weeks.

Positive

• Introduction of innovative 'exozymes' technology potentially solving industrial scaling challenges in synthetic biology
• AI-powered development process significantly reduces chemical production timelines from months to weeks
• Technology enables sustainable production of valuable chemicals, medicines, and biofuels

Negative

• None.

Insights

Technology Innovation Analyst

The strategic rebranding to eXoZymes marks a pivotal evolution in the industrial biotechnology sector, introducing a potentially disruptive platform that bridges the critical gap between synthetic biology research and commercial-scale production. The company's AI-engineered enzyme technology addresses a fundamental challenge that has historically plagued the synthetic biology field - the ability to scale efficiently to industrial levels.

The platform's most compelling value proposition lies in its accelerated development cycle. Traditional chemical process development typically requires 6-18 months of R&D, while eXoZymes claims to reduce this to weeks. This 10-20x acceleration in development time could revolutionize the economics of specialty chemical and pharmaceutical production, particularly for:

• Custom pharmaceutical intermediates and APIs
• High-value specialty chemicals
• Sustainable biofuels

The decision to introduce 'exozymes' as an unprotected scientific term, rather than a trademarked brand, suggests confidence in their technology's potential to establish a new industry standard. This approach mirrors historical precedents where pioneering companies established new technological categories, such as CRISPR in gene editing.

The platform's cell-free nature offers several competitive advantages over traditional synthetic biology approaches:

• Reduced complexity in scaling processes
• Lower contamination risks
• More precise control over reaction conditions
• Potential for continuous production systems

However, the success of this rebranding and technological approach will ultimately depend on demonstrating consistent commercial-scale production capabilities and cost advantages over existing chemical synthesis methods. The upcoming announcement of their rapid-development chemical product will be a important proof point for validating their platform's capabilities.

• Rebranding Invizyne Technologies, Inc to eXoZymes Inc.
• Changing NASDAQ ticker from IZTC to EXOZ
• Introducing but not trademarking “exozymes” as a new scientific nomenclature

Monrovia, California, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Today, Invizyne Technologies, Inc. - a pioneer of AI-engineered enzymes that can sustainably transform feedstock into essential chemicals, medicines, and biofuels, announced a corporate name change to eXoZymes, Inc. (“eXoZymes”) and that its common stock will begin trading on the Nasdaq Capital Market under the new ticker symbol of “EXOZ” effective before the market open.

No action is required by existing shareholders with respect to the name and ticker symbol change. The Committee on Uniform Securities Identification Procedures (CUSIP) also confirmed the CUSIP number assigned to the Company's common stock will remain unchanged.

“In response to feedback from our stakeholders and us having to continually explain which kind of ‘cell-free’ technology our platform falls under, we’re rebranding to both bring clarity around our core technology as well as set us apart from existing technologies. In fact, we believe that our technology is so fundamental and has so much potential that trying to label it with existing nomenclature falls short, which is why we’re introducing ‘exozymes’ as scientific concept,” states CEO of eXoZymes, Michael Heltzen. “We view exozymes as the logical successor to synthetic biology (SynBio), as they essentially represent the missing last step for most SynBio projects: Scaling on an industrial level, which is fundamental for economic success but mostly has eluded the SynBio space this far.”

“For the first time in history, we now have the tools and insight to control and optimize nature’s biological processes, enabling us to replace traditional chemical production methods with a sustainable and eco-friendly alternative: Exozymes. Exozymes are advanced enzymes engineered using AI to thrive in a bioreactor outside of living cells that now allow us to efficiently transform affordable and widely available feedstocks into a diverse range of valuable small-molecule chemicals, including active pharmaceutical ingredients, nutraceuticals, and biofuel,” said Tyler Korman, PhD, co-founder and VP of Research at eXoZymes. “As an example of how combining AI with enzymes speeds up the development process, relatively soon we anticipate announcing a new chemical that we took from idea to actual production in weeks. That short development cycle is a paradigm shift in itself.”

About eXoZymes Inc.
Founded in 2019, the company has developed a platform that - as a historic first - offers the tools and insight to control and optimize nature’s own biological processes, enabling their partners to replace traditional chemical production methods with a new sustainable and non-polluting alternative: Exozymes.

Exozymes are advanced enzymes engineered using AI to thrive in a bioreactor outside of living cells. Exozymes can replace toxic petrochemical processes and inefficient biochemical extraction with sustainable and scalable biosolutions to more efficiently transform biomass into essential chemicals, medicines, and biofuels.

By freeing enzyme-driven chemical reactions from the limitations imposed by cellular environments, exozyme biosolutions eliminate the scaling bottleneck that has hampered commercial success in the synthetic biology (SynBio) space, making exozymes the natural successor to most synthetic biology projects.

Inspired by insights from four recent Nobel Prizes in Chemistry, this technological platform ushers in the exozyme era - a paradigm shift in chemical production by introducing scalable and sustainable exozyme biosolutions.

While the company, eXoZymes Inc., has introduced “exozymes” (エキソザイム in Japanese katakana) as a scientific concept, they are not trademarking the concept, as they view it as a new nomenclature for wide adoption.

Learn more on exozymes.com.

Forward-Looking Statements
This press release contains "forward-looking statements." These forward-looking statements are made as of the date they were first issued and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as “aim”, "expect," "anticipate," "should," "believe," "hope," "target," "project," "goals," "estimate," "potential," "predict," "may," "will," "might," "could," "intend," "shall" and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements.

Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond eXoZymes’ control. eXoZymes’ actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors. The forward-looking statements included in this press release represent eXoZymes’ views as of the date of this press release. eXoZymes anticipates that subsequent events and developments will cause its views to change. eXoZyme’s undertakes no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing eXoZymes’ views as of any date subsequent to the date of this press release.

Media contacts
Lasse Görlitz, VP of Communications
(858) 319-7135
press@exozymes.com 

Investor Relations Contact: 
IR@exozymes.com 

FAQ

What is the new stock symbol for eXoZymes (formerly Invizyne) on Nasdaq?

eXoZymes will trade under the new ticker symbol EXOZ on the Nasdaq Capital Market.

How does eXoZymes' AI-engineered enzyme technology work?

eXoZymes' technology uses AI-engineered enzymes that operate in bioreactors outside living cells to transform feedstocks into chemicals, medicines, and biofuels.

What advantage does EXOZ's exozymes technology have over traditional synthetic biology?

The main advantage is its ability to scale at an industrial level, which has been a significant challenge for traditional synthetic biology projects.

How fast can EXOZ develop new chemicals using their AI-enzyme technology?

According to the company, they can develop new chemicals from idea to production in weeks, representing a significant acceleration compared to traditional methods.